Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
51.9 USD | +2.51% | -3.21% | -6.49% |
May. 15 | Stifel Adjusts Price Target on Arcellx to $83 From $82, Maintains Buy Rating | MT |
May. 14 | Evercore ISI Starts Arcellx With Outperform Rating | MT |
Business Summary
Number of employees: 130
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cell Therapies
100.0
%
| 0 | nan % | 110 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 110 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Rami Elghandour
CEO | Chief Executive Officer | 45 | 21-01-21 |
Michelle Gilson
DFI | Director of Finance/CFO | 32 | 22-05-22 |
David Tice
CTO | Chief Tech/Sci/R&D Officer | 53 | 20-03-31 |
Narinder Singh
CTO | Chief Tech/Sci/R&D Officer | 51 | 21-09-30 |
Chief Tech/Sci/R&D Officer | 44 | 21-03-31 | |
Myesha Lacy
IRC | Investor Relations Contact | - | 21-05-31 |
General Counsel | - | 22-06-20 | |
Aileen Fernandes
PRN | Corporate Officer/Principal | - | 20-12-31 |
Kate Aiken
HRO | Human Resources Officer | - | 12-12-31 |
Neeraj Teotia
PRN | Corporate Officer/Principal | 49 | 21-03-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David Lubner
BRD | Director/Board Member | 60 | 20-07-31 |
Ali Behbahani
BRD | Director/Board Member | 48 | 15-01-31 |
Rami Elghandour
CEO | Chief Executive Officer | 45 | 21-01-21 |
Jill Carroll
BRD | Director/Board Member | 48 | 17-08-31 |
Kavita Patel
BRD | Director/Board Member | 50 | 21-11-30 |
Derek Yoon
BRD | Director/Board Member | 49 | 20-03-31 |
Olivia Ware
BRD | Director/Board Member | 67 | 22-05-15 |
Hong Xia Wang
BRD | Director/Board Member | 48 | 21-04-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 53,502,572 | 42,713,403 ( 79.83 %) | 0 | 79.83 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.49% | 2.78B | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- ACLX Stock
- Company Arcellx, Inc.